Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Tadalafil Tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and...
Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr®...
Global pharmaceutical company Mylan N.V.'s (NASDAQ: MYL) board of directors today released the following statement: Over the past decade, Mylan's Board of Directors and management team have turned...
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and six months ended June 30, 2018. Second Quarter 2018 Financial Highlights Total revenues of $2.81 billion, down 5%...
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2018 financial results, on Wed., Aug. 8, before the open of the U.S. financial...
Educational materials to help empower your customers.
What to know about our high quality generics.
Details about our brand name and generic medicines.
Resources that meet the specific needs of your institution.
Copyright © 2018 Mylan N.V. All Rights Reserved.
For U.S. Audiences Only
Please select one of our websites from the list below.
Mylan also is proud to do business in these locations.